Ireland

--:--IST

Latest

Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide

Subscribe

Registers› Irish medicines ›Stallergenes

Medicines register · Ireland

Stallergenes — licensed medicines

10 medicines held by Stallergenes on the Irish market, from the HPRA register.

Source: HPRA open dataset ("Authorised or Transfer Pending Products"), CC BY 4.0. Complete coverage — all 10,295 authorised products are in this register. Synced 06 Oct 2026, 03:23 UTC

Narrow the register Reset

Search within results

Matches brand name, active substance, licence holder and licence number.

Browse by first letter

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Medicine

Active substance

Licence holder

Status

ACTAIR 100 IR & 300 IR sublingual tablets PA2113/002/002

Dermatophagoides Pteronyssinus Extract, Dermatophagoides Farinae Extract

Marketed

ACTAIR 100 IR sublingual tablets PA2113/002/001

Dermatophagoides Pteronyssinus Extract, Dermatophagoides Farinae Extract

Marketed

ACTAIR 300 IR sublingual tablets PA2113/002/003

Dermatophagoides Pteronyssinus Extract, Dermatophagoides Farinae Extract

Marketed

Oralair 100IR & 300IR sublingual tablets PA2113/001/001

Grass pollen allergen extract

Marketed

Oralair 300 IR sublingual tablets PA2113/001/002

Grass pollen allergen extract

Marketed

Palforzia 0.5 mg oral powder in capsules for opening Palforzia 1 mg oral powder in capsules for opening EU/1/20/1495/001

Arachis Hypogaea Allergens

—

Palforzia 1 mg oral powder in capsules for opening EU/1/20/1495/002-003

Arachis Hypogaea Allergens

—

Palforzia 10 mg oral powder in capsules for opening Palforzia 1 mg oral powder in capsules for opening EU/1/20/1495/004

Arachis Hypogaea Allergens

—

Palforzia 100 mg oral powder in capsules for opening EU/1/20/1495/011

Arachis Hypogaea Allergens

—

Palforzia 300 mg oral powder in sachet EU/1/20/1495/012-013

Arachis Hypogaea Allergens

—

Cite this view

Priya Life Science (2026). Irish Medicines Register, filtered. Derived from the HPRA open dataset. Retrieved 6 October 2026. https://priyalifescience.com/medicines/company/stallergenes

Download this register

GET /api/export.php?register=medicines-ie&format=csv Try the JSON export →

Regulatory information only — not medical advice. For the authoritative record see the HPRA register directly.